Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
The transaction is expected to close in Q2 FY 2026
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Annual EBITDA margin expands by 170 basis points
Akums invested Rs. 272 crore in capital expenditure during FY25
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
Subscribe To Our Newsletter & Stay Updated
